SNDXSyndax Pharmaceuticals, Inc.
$16.99+15% 1Y
$16.99
$13.1152 weeks$25.15
SNDX in its own filings
Nothing in SNDX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
186
Events found in the filings · across 653 filings · the record starts in 2015
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 22, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 2, 2026
- SEC comment-letter activity15 occurrences
- 2023-12-07
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jul 14, 2026On July 14, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation highlighting its late-stage programs and the next chapter of its R&D strategy, including new pipeline assets, during its R&D event held on July 14, 2026.Other event · Form 8-K
- Jun 10, 2026Entry into a Material Agreement.Material agreement entered · Form 8-K
- Jun 10, 2026At the Syndax Pharmaceuticals, Inc. (the “Company”) 2026 Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders approved the Company’s 2026 Equity Incentive Plan (the “2026 Plan”), which the Board of Directors of the Company (the “Board”) previously approved, subject to stockholder approval …Director or officer change · Form 8-K
- Jun 4, 2026Entry into a Material Agreement.Material agreement entered · Form 8-K
- Apr 30, 2026Syndax Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Feb 26, 2026Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Jan 12, 2026Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44 th Annual J.P. Morgan Healthcare Conference.Earnings release · press release
- Dec 19, 2025On December 18, 2025, the Board of Directors of Syndax Pharmaceuticals Inc. (the “Company”) approved amendments to the Amended and Restated Bylaws (the “Bylaws”) of the Company, effective on such date.Charter/bylaw amendment or fiscal-year change · Form 8-K
- Nov 3, 2025Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
- Oct 24, 2025On October 24, 2025, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) for the treatment of relapsed or refractory (“R/R”) acute myeloid leukemia (“AML”) with a susceptible nucleophosmin 1 (“NPM1”) mutation in …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…